IVIG Denied by Insurance? How to Win Your Appeal

Intravenous immunoglobulin (IVIG) therapy is a lifeline for patients with serious autoimmune and immunodeficiency disorders — yet insurers deny it at alarming rates. Whether your diagnosis is primary immunodeficiency, CIDP, myasthenia gravis, or another condition with strong clinical support, an IVIG denial is not the end. Federal law gives you the right to appeal, and independent External Independent Review: Complete Guide" class="auto-link">external reviews overturn insurer denials in approximately 40–50% of IVIG cases. This guide explains exactly how to fight back.

Why Insurers Deny IVIG

Insurance companies deny IVIG claims for several recurring reasons, most of which can be effectively challenged with the right documentation and legal citations.

"Not medically necessary." This is the most common denial reason. The insurer's medical reviewer claims your condition does not meet their internal clinical criteria for IVIG. These internal criteria often lag behind current medical literature by years. Under ACA Section 2719 (42 U.S.C. § 300gg-19), insurers must base medical necessity determinations on current clinical standards — not outdated internal guidelines.

"Experimental or investigational." Insurers frequently label IVIG as experimental for off-label uses, even when decades of peer-reviewed evidence support the treatment. The FDA itself acknowledges that off-label prescribing is standard medical practice (FDA Off-Label Use Guidance). If your condition has supporting evidence in AAAAI or AAN guidelines, the "experimental" designation rarely survives scrutiny.

"Dosage or frequency exceeds plan limits." Some insurers approve IVIG but cap the dosage or infusion frequency, even when your physician prescribes a higher regimen. IVIG dosing is highly individualized based on body weight and clinical response — cookie-cutter limits often conflict directly with published clinical guidelines.

"Site of service restriction." Your plan may require IVIG at a hospital outpatient facility rather than a home infusion service, or vice versa. These restrictions may add cost or inconvenience without any clinical justification.

How to Appeal an IVIG Denial

Step 1: Request the Complete Denial Letter and Claims File

Your denial letter must explain the specific clinical criteria used, the credentials of the reviewing physician, and your appeal rights and deadlines. Under ERISA Section 1133 (29 U.S.C. § 1133) and ACA Section 2719, you are entitled to the full claims file, including internal reviewer notes and the clinical policy bulletin applied to your case. Request these documents immediately.

Step 2: Obtain a Detailed Letter of Medical Necessity

Ask your treating physician to write a comprehensive letter explaining your diagnosis, complete treatment history, why IVIG is the appropriate standard of care, and why alternatives are insufficient. The letter should specifically reference clinical guidelines from the AAAAI, the American Academy of Neurology (AAN), or the Primary Immune Deficiency Treatment Consortium, as applicable to your condition.

Step 3: Gather Supporting Clinical Evidence

Compile peer-reviewed studies, clinical guidelines, and consensus statements that support IVIG for your specific condition. The AAN Practice Parameter updates for CIDP and other neuromuscular disorders are particularly useful. For immunodeficiency, the AAAAI and the Immune Deficiency Foundation publish clinical practice guidelines that carry significant weight in appeals.

Step 4: Write a Point-by-Point Appeal Letter

Your appeal letter should systematically address each denial reason with specific evidence. Cite ACA Section 2719 and your right to independent external review. Reference ERISA Section 502 if your plan is employer-sponsored — it requires the insurer to provide a full and fair review. State the specific outcome you are requesting and include a deadline for response.

Step 5: Submit and Request Expedited Review if Needed

If your condition is urgent, federal law requires the insurer to provide an expedited appeal decision within 72 hours under ACA Section 2719(b)(1). Clearly state in your appeal why a delay would jeopardize your health. Submit your appeal by certified mail and through the insurer's member portal. Keep copies of everything.

Step 6: Escalate to External Review if the Internal Appeal Fails

Under ACA Section 2719, all non-grandfathered health plans must provide access to an independent external review (IRO). The IRO's decision is binding on the insurance company. External reviews overturn IVIG denials at approximately 40–50% nationally. You typically have 60 days after an internal denial to request external review.

What to Include in Your IVIG Appeal

• Your denial letter with the specific reason and clinical criteria highlighted
• Physician letter of medical necessity with ICD-10 diagnosis codes
• Clinical guidelines from AAAAI, AAN, or other relevant specialty societies
• Peer-reviewed studies supporting IVIG for your specific condition
• Complete treatment history documenting why alternatives were tried or are inappropriate
• Documentation of functional impairment or disease progression without IVIG
• Citation to ACA Section 2719 and your right to external review
• Any applicable state IVIG access laws (several states have enacted specific IVIG coverage mandates)

Fight Back With ClaimBack

IVIG denials are among the most frequently overturned insurance decisions in external review — because the clinical evidence is strong and the legal protections are clear. A well-structured appeal citing the AAAAI guidelines, AAN practice parameters, and ACA Section 2719 gives you a real path to approval. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal